explore -WSS

explore

author：knowledge 2025-09-02 11:48:22 - browse：22

A pile of Zynex Medical batteries and electrode pads are seen at Michelle Bean's home — A pile of Zynex Medical batteries and electrode pads Kayana Szymczak for STAT

Sending patients heaps of medical supplies to score more money from insurers is common in the device industry. If insurers decline to cover the supplies, patients are stuck paying for materials they didn’t need.

STAT examined one of the companies perpetuating this practice, a pain management device company called Zynex Medical, and the frustration among both its patients and former employees. Here are five takeaways.

The ‘razor blade’ business model

Zynex sells nerve and muscle stimulation machines, known as TENS and EMS units, to treat pain and soothe muscles. But the company makes most of its money from monthly shipments of batteries and electrodes — almost 70% of its $184 million revenue in 2023 came from these supplies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Study: AI not yet building 'n

WSS

Apple Watch's A

Lawmakers grill UnitedHealth CEO on Change cyberattack

First recipient of genetically engineered pig kidney has died

HHS's proposed rule does nothing to address the climate crisis

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

As health system earnings go up, health insurance stocks go down

focus

explore

The ‘razor blade’ business model

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

explore

As demand for Covid shots wanes, Moderna seeks its next success

Sanofi strikes deal with Novavax, boosting the vaccine maker

After affirmative action ruling, medical educators look to 'holistic review'

H5N1 bird flu: what we're starting to learn about infection in cows

Continuity nursing helped my family in our darkest PICU moments

Apple Watch's A

Alkermes shareholders re

Brain worms: The science behind RFK Jr.'s parasitic infection

Supreme Court strikes down use of affirmative action

The effects of a landmark ruling on DNA ownership are becoming clearer

hotspot

Dairy farmers resist CDC push for PPE against bird flu virus

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

HHS's proposed rule does nothing to address the climate crisis

Researchers on aging grapple with how to calculate biological age

H5N1 bird flu: what we're starting to learn about infection in cows

Telehealth startups turn to complex chronic diseases

hotspot

entertainment

knowledge

focus